{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:22Z","timestamp":1786650142113,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"abstract":"\n Background:<\/jats:title>\n The present understanding of the clinical course, complications, and outcome of myasthenic crisis (MC) is based chiefly on observational studies and retrospective case series.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n To study the baseline demographic and clinical variables, risk factors, complications, outcome, and mortality in patients of MC.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n All patients of myasthenia gravis (MG) who presented with myasthenic crisis between July 2009 and December 2010 were included.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Ten patients of MC were included in this study. The median age of the patients was 40.5 years (range 14-71 years). Seven were females and three were males. Nine had generalized MG and one patient had oculobulbar involvement only. Median duration of disease was 3 years (range 1 month to17 years). Two patients had thymoma. Two patients had history of thymectomy in the past. Infection was the most common triggering factor accounting for five cases (50%) followed by inadequate treatment\/drug withdrawal in three (30%) and steroid initiation and hypokalemia in the remaining two patients (20%). Median duration of MC was 12 days (range 3-28 days). Mortality was in 3 out of 10 (30%) during MC. Management in the intensive care unit (ICU) and treatment with plasma exchange\/intravenous immunoglobulins were associated with good outcome.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Ventilator support and management in intensive care unit are the most important components in the management of MC. The high mortality rate seen in present study may be more reflective of the actual ground reality in resource constrained developing countries, however, larger prospective studies are needed to confirm these findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/0972-2327.112466","type":"journal-article","created":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T04:37:35Z","timestamp":1369370255000},"page":"203-207","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Clinical profile and outcome of myasthenic crisis in a tertiary care hospital"],"prefix":"10.4103","volume":"16","author":[{"given":"Sudhir","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudesh","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-16-20260109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","article-title":"Myasthenic crisis","volume":"102","author":"Chaudhuri","year":"2009","journal-title":"QJM"},{"key":"R3-16-20260109","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"key":"R4-16-20260109","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1749-6632.1981.tb33765.x","article-title":"Aspects of the natural history of myasthenia gravis: Crisis and death","volume":"377","author":"Cohen","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"R5-16-20260109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-2004-829595","article-title":"Myasthenia gravis: Management of myasthenic crisis and perioperative care","volume":"24","author":"Juel","year":"2004","journal-title":"Semin Neurol"},{"key":"R6-16-20260109","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00007611-197010000-00007","article-title":"Aspects of treatment of crisis in myasthenia gravis","volume":"63","author":"Jenkins","year":"1970","journal-title":"South Med J"},{"key":"R7-16-20260109","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jnnp.45.3.217","article-title":"Ventilatory failure in myasthenia gravis","volume":"45","author":"Ferguson","year":"1982","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R8-16-20260109","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0025-6196(25)18832-0","article-title":"Mechanical ventilation for respiratory failure in myasthenia gravis. Two-year experience with 22 patients","volume":"58","author":"Gracey","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"R9-16-20260109","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/00007611-198510000-00017","article-title":"Treatment of myasthenic crisis in late life","volume":"78","author":"Sellman","year":"1985","journal-title":"South Med J"},{"key":"R10-16-20260109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin Neurol"},{"key":"R11-16-20260109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: Guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"R12-16-20260109","first-page":"453","article-title":"Myasthenic crisis: A retrospective study","volume":"52","author":"Panda","year":"2004","journal-title":"Neurol India"},{"key":"R13-16-20260109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0028-3886.15050","article-title":"Myasthenic crisis: Clinical features, complications and mortality","volume":"53","author":"Murthy","year":"2005","journal-title":"Neurol India"},{"key":"R14-16-20260109","first-page":"348","article-title":"Intensive respiratory care in patients with myasthenic crisis","volume":"50","author":"Aggarwal","year":"2002","journal-title":"Neurol India"},{"key":"R15-16-20260109","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1212\/WNL.16.5.431","article-title":"Myasthenia gravis: Evaluation of treatment in 1,355 patients","volume":"16","author":"Perlo","year":"1966","journal-title":"Neurology"},{"key":"R16-16-20260109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"R18-16-20260109","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"R19-16-20260109","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0002-8703(75)90330-0","article-title":"The heart in myasthenia gravis","volume":"90","author":"Gibson","year":"1975","journal-title":"Am Heart J"},{"key":"R20-16-20260109","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00019052-199806000-00007","article-title":"Inflammatory myopathy in myasthenia gravis","volume":"11","author":"Aarli","year":"1998","journal-title":"Curr Opin Neurol"},{"key":"R21-16-20260109","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1. 4 in a severe form of myasthenia gravis","volume":"170","author":"Suzuki","year":"2005","journal-title":"J Neuroimmunol"},{"key":"R22-16-20260109","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol"},{"key":"R23-16-20260109","first-page":"179","article-title":"Cardiac involvement in myasthenia gravis--is there a specific pattern?","volume":"47","author":"Calin","year":"2009","journal-title":"Rom J Intern Med"},{"key":"R24-16-20260109","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/S0004-282X2002000400001","article-title":"Myasthenic crisis: Report of 24 cases","volume":"60","author":"Werneck","year":"2002","journal-title":"Arq Neuropsiquiatr"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223306-201316020-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:04:15Z","timestamp":1786647855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223306-201316020-00016"}},"subtitle":["A prospective study"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.4103\/0972-2327.112466","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}